A8 LBC test in self-collection participants positive for oncogenic HPV (not 16/18)

Table A8.1a: Proportion of participants who self-collected a sample for their primary screening HPV test that detected oncogenic HPV (not 16/18) who had an LBC test within 3 months, by age, 2024

Age group

Number

Crude rate (%)

25–29

6,865

74.3

30–34

3,663

74.9

35–39

2,835

74.7

40–44

2,351

77.0

45–49

1,956

77.8

50–54

2,050

79.6

55–59

1,922

80.8

60–64

2,002

82.5

65–69

1,675

83.3

70–74

844

61.1

25–74

26,163

76.3

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A8.1b: Proportion of participants who self-collected a sample for their primary screening HPV test that detected oncogenic HPV (not 16/18) who had an LBC test within 6 months, by age, 2024

Age group

Number

Crude rate (%)

25–29

7,743

83.8

30–34

4,081

83.4

35–39

3,204

84.4

40–44

2,636

86.3

45–49

2,189

87.1

50–54

2,284

88.7

55–59

2,116

88.9

60–64

2,196

90.5

65–69

1,836

91.3

70–74

1,086

78.6

25–74

29,371

85.7

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A8.2a: Proportion of participants who self-collected a sample for their primary screening HPV test that detected oncogenic HPV (not 16/18) who had an LBC test within 3 months, participants aged 25–74, 2018 to 2024

Year

Number

Crude rate (%)

2018

63

52.1

2019

122

46.2

2020

105

52.0

2021

170

48.2

2022

2,280

66.6

2023

13,278

75.5

2024

26,163

76.3

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A8.2b: Proportion of participants who self-collected a sample for their primary screening HPV test that detected oncogenic HPV (not 16/18) who had an LBC test within 6 months, participants aged 25–74, 2018 to 2024

Year

Number

Crude rate (%)

2018

81

66.9

2019

157

59.5

2020

121

59.9

2021

206

58.4

2022

2,656

77.6

2023

14,958

85.1

2024

29,371

85.7

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Previous page
Next page